Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: facilitating research through infrastructure, workforce, resources and funding.

Blueprint National Hemophilia Foundation collaboration community funding infrastructure inherited bleeding disorders network resource development workforce development

Journal

Expert review of hematology
ISSN: 1747-4094
Titre abrégé: Expert Rev Hematol
Pays: England
ID NLM: 101485942

Informations de publication

Date de publication:
03 2023
Historique:
entrez: 15 3 2023
pubmed: 16 3 2023
medline: 21 3 2023
Statut: ppublish

Résumé

The National Hemophilia Foundation (NHF) conducted extensive, inclusive community consultations to guide prioritization of research in coming decades in alignment with its mission to find cures and address and prevent complications enabling people and families with blood disorders to thrive. With the American Thrombosis and Hemostasis Network, NHF recruited multidisciplinary expert working groups (WG) to distill the community-identified priorities into concrete research questions and score their feasibility, impact, and risk. WG6 was charged with identifying the infrastructure, workforce development, and funding and resources to facilitate the prioritized research. Community input on conclusions was gathered at the NHF State of the Science Research Summit. WG6 detailed a minimal research capacity infrastructure threshold, and opportunities to enable its attainment, for bleeding disorders centers to participate in prospective, multicenter national registries. They identified challenges and opportunities to recruit, retain, and train the diverse multidisciplinary care and research workforce required into the future. Innovative collaborative approaches to trial design, resource networking, and funding to surmount obstacles facing research in rare disorders were elucidated. The innovations in infrastructure, workforce development, and resources and funding proposed herein may contribute to facilitating a National Research Blueprint for Inherited Bleeding Disorders. Research is critical to advancing the diagnosis and care of people with inherited bleeding disorders (PWIBD). This research requires significant infrastructure, including people and resources. Hemophilia treatment centers (HTC) need many different skilled care professionals including doctors, nurses, and other providers; also statisticians, data managers, and other experts to process patients’ clinical information into research. Attracting diverse qualified professionals to the clinical and research work requires long-term planning, recruiting individuals in training programs and retaining them as they become experts. Research infrastructure includes physical servers running database software, networks that link them, and the environment in which these components function. US Centers for Disease Control and Prevention (CDC) and American Thrombosis and Hemostasis Network (ATHN) coordinate and fund data collection at HTCs on the health and well-being of thousands of PWIBD into a registry used in research studies.National Hemophilia Foundation (NHF) and ATHN asked our group of health care professionals, technology experts, and lived experience experts (LEE) to identify the infrastructure, workforce, and resources needed to do the research most important to PWIBD. We identified the types of CDC/ATHN studies all HTCs should be able to perform, and the physical and human infrastructure this requires. We prioritized finding the best clinical trial designs to study inherited bleeding disorders, identifying ways to share personnel and tools between HTCs, and innovating how research is governed and funded. Involving LEEs in designing, managing, and carrying out research will be key in conducting research to improve the lives of PWIBD.

Sections du résumé

BACKGROUND
The National Hemophilia Foundation (NHF) conducted extensive, inclusive community consultations to guide prioritization of research in coming decades in alignment with its mission to find cures and address and prevent complications enabling people and families with blood disorders to thrive.
RESEARCH DESIGN AND METHODS
With the American Thrombosis and Hemostasis Network, NHF recruited multidisciplinary expert working groups (WG) to distill the community-identified priorities into concrete research questions and score their feasibility, impact, and risk. WG6 was charged with identifying the infrastructure, workforce development, and funding and resources to facilitate the prioritized research. Community input on conclusions was gathered at the NHF State of the Science Research Summit.
RESULTS
WG6 detailed a minimal research capacity infrastructure threshold, and opportunities to enable its attainment, for bleeding disorders centers to participate in prospective, multicenter national registries. They identified challenges and opportunities to recruit, retain, and train the diverse multidisciplinary care and research workforce required into the future. Innovative collaborative approaches to trial design, resource networking, and funding to surmount obstacles facing research in rare disorders were elucidated.
CONCLUSIONS
The innovations in infrastructure, workforce development, and resources and funding proposed herein may contribute to facilitating a National Research Blueprint for Inherited Bleeding Disorders.
Research is critical to advancing the diagnosis and care of people with inherited bleeding disorders (PWIBD). This research requires significant infrastructure, including people and resources. Hemophilia treatment centers (HTC) need many different skilled care professionals including doctors, nurses, and other providers; also statisticians, data managers, and other experts to process patients’ clinical information into research. Attracting diverse qualified professionals to the clinical and research work requires long-term planning, recruiting individuals in training programs and retaining them as they become experts. Research infrastructure includes physical servers running database software, networks that link them, and the environment in which these components function. US Centers for Disease Control and Prevention (CDC) and American Thrombosis and Hemostasis Network (ATHN) coordinate and fund data collection at HTCs on the health and well-being of thousands of PWIBD into a registry used in research studies.National Hemophilia Foundation (NHF) and ATHN asked our group of health care professionals, technology experts, and lived experience experts (LEE) to identify the infrastructure, workforce, and resources needed to do the research most important to PWIBD. We identified the types of CDC/ATHN studies all HTCs should be able to perform, and the physical and human infrastructure this requires. We prioritized finding the best clinical trial designs to study inherited bleeding disorders, identifying ways to share personnel and tools between HTCs, and innovating how research is governed and funded. Involving LEEs in designing, managing, and carrying out research will be key in conducting research to improve the lives of PWIBD.

Autres résumés

Type: plain-language-summary (eng)
Research is critical to advancing the diagnosis and care of people with inherited bleeding disorders (PWIBD). This research requires significant infrastructure, including people and resources. Hemophilia treatment centers (HTC) need many different skilled care professionals including doctors, nurses, and other providers; also statisticians, data managers, and other experts to process patients’ clinical information into research. Attracting diverse qualified professionals to the clinical and research work requires long-term planning, recruiting individuals in training programs and retaining them as they become experts. Research infrastructure includes physical servers running database software, networks that link them, and the environment in which these components function. US Centers for Disease Control and Prevention (CDC) and American Thrombosis and Hemostasis Network (ATHN) coordinate and fund data collection at HTCs on the health and well-being of thousands of PWIBD into a registry used in research studies.National Hemophilia Foundation (NHF) and ATHN asked our group of health care professionals, technology experts, and lived experience experts (LEE) to identify the infrastructure, workforce, and resources needed to do the research most important to PWIBD. We identified the types of CDC/ATHN studies all HTCs should be able to perform, and the physical and human infrastructure this requires. We prioritized finding the best clinical trial designs to study inherited bleeding disorders, identifying ways to share personnel and tools between HTCs, and innovating how research is governed and funded. Involving LEEs in designing, managing, and carrying out research will be key in conducting research to improve the lives of PWIBD.

Identifiants

pubmed: 36920855
doi: 10.1080/17474086.2023.2181781
doi:

Types de publication

Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

107-127

Auteurs

Margaret V Ragni (MV)

Department of Hematology/Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Medical and Scientific Advisory Council, National Hemophilia Foundation, New York, New York, USA.

Guy Young (G)

Cancer and Blood Disorders Institute, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California, USA.

Glaivy Batsuli (G)

Department of Pediatrics, Emory University, Atlanta, Georgia, USA.
Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta, Atlanta, Georgia, USA.

Emily Bisson (E)

Hemostasis & Thrombosis Center, Connecticut Children's, Hartford, Connecticut, USA.

Shannon L Carpenter (SL)

Department of Pediatric Hematology/Oncology, Children's Mercy Hospital, Kansas City, Missouri, USA.

Stacy E Croteau (SE)

Boston Hemophilia Treatment Center, Boston Children's Hospital, Boston, Massachusetts, USA.
Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.

Adam Cuker (A)

Penn Comprehensive Hemophilia Program, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Randall G Curtis (RG)

Hematology Utilization Group Study (HUGS), University of Southern California, Los Angeles, California, USA.
Patient Reported Outcomes, Burdens and Experiences (PROBE) Washington, DC, USA.

Michael Denne (M)

Hematology and Rare Disease, Takeda, Cincinnati, Ohio, USA.

Bruce Ewenstein (B)

Takeda Development Center Americas, Inc, Cambridge, Massachusetts, USA.

Amber Federizo (A)

Hemostasis and Thrombosis Center of Nevada, Las Vegas, Nevada, USA.

Neil Frick (N)

National Hemophilia Foundation, New York, New York, USA.

Kerry Funkhouser (K)

Foundation for Women & Girls with Blood Disorders, Montclair, New Jersey, USA.

Lindsey A George (LA)

Department of Hematology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

W Keith Hoots (WK)

Division of Blood Diseases and Resources, National Heart, Lung and Blood Institute, National Institutes of Health; Health and Human Services, Bethesda, Maryland, USA.

Shawn M Jobe (SM)

Department of Pediatrics and Human Development, Michigan State University College of Medicine, East Lansing, Michigan, USA.

Emily Krava (E)

Department of Hematology-Oncology, Children's Hospital Los Angeles, Los Angeles, California, USA.

Christopher James Langmead (CJ)

Department of Computational Biology, Carnegie Mellon University, Pittsburgh, Pennsylvania, USA.

Roger J Lewis (RJ)

Berry Consultants, LLC, Austin, Texas, USA.

José López (J)

Bloodworks Northwest, Seattle, Washington, USA.
Department of Hematology, University of Washington, School of Medicine, Seattle, Washington, USA.

Lynn Malec (L)

Blood Research Institute, Versiti, Milwaukee, Wisconsin, USA.

Ziva Mann (Z)

National Hemophilia Foundation, New York, New York, USA.
Ascent Leadership Networks, Newton, Massachusetts, USA.

Moses E Miles (ME)

American Thrombosis and Hemostasis Network, Rochester, New York, USA.

Emma Neely (E)

National Hemophilia Foundation, New York, New York, USA.

Ellis J Neufeld (EJ)

Department of Hematology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Department of Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

Glenn F Pierce (GF)

World Federation of Hemophilia, Montréal, Québec, Canada.

Steven W Pipe (SW)

Medical and Scientific Advisory Council, National Hemophilia Foundation, New York, New York, USA.
Division of Pediatric Hematology and Oncology, University of Michigan, Ann Arbor, Michigan, USA.

Lisa R Pitler (LR)

Alliance for Clinical Trials in Oncology Foundation, Chicago, Illinois, USA.

Leslie Raffini (L)

Hemostasis and Thrombosis Center, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

Kathaleen M Schnur (KM)

Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, USA.

Jordan A Shavit (JA)

Division of Pediatric Hematology and Oncology, University of Michigan, Ann Arbor, Michigan, USA.
Human Genetics, University of Michigan, Ann Arbor.
Hemophilia and Coagulation Disorders Program, University of Michigan, Ann Arbor, Michigan, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH